These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 34571271)

  • 21. Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy.
    Qian Y; Sun Y; Shi P; Zhou X; Zhang Q; Dong Q; Jin S; Qiu L; Niu X; Zhou X; Zhao W; Wu Y; Zhai W; Gao Y
    Acta Pharm Sin B; 2024 Mar; 14(3):1150-1165. PubMed ID: 38486998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.
    Qian W; Zhao M; Wang R; Li H
    J Hematol Oncol; 2021 Sep; 14(1):147. PubMed ID: 34526102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipid-Polymer Hybrid Nanoparticles with Both PD-L1 Knockdown and Mild Photothermal Effect for Tumor Photothermal Immunotherapy.
    Chuan D; Fan R; Chen B; Ren Y; Mu M; Chen H; Zou B; Dong H; Tong A; Guo G
    ACS Appl Mater Interfaces; 2023 Sep; 15(36):42209-42226. PubMed ID: 37605506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A tumor microenvironment responsive biodegradable CaCO
    Liu Y; Pan Y; Cao W; Xia F; Liu B; Niu J; Alfranca G; Sun X; Ma L; de la Fuente JM; Song J; Ni J; Cui D
    Theranostics; 2019; 9(23):6867-6884. PubMed ID: 31660074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual-Blockade Immune Checkpoint for Breast Cancer Treatment Based on a Tumor-Penetrating Peptide Assembling Nanoparticle.
    Li G; Gao Y; Gong C; Han Z; Qiang L; Tai Z; Tian J; Gao S
    ACS Appl Mater Interfaces; 2019 Oct; 11(43):39513-39524. PubMed ID: 31599562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spatiotemporal-Controlled NIR-II Immune Agonist Sensitizes Cancer Immunotherapy.
    Guo S; Tang D; Zhang M; Yang H; Zhang T; Hu B; Xu C; Weng Y; Shang K; Huang Y
    Adv Mater; 2024 Jun; 36(25):e2400228. PubMed ID: 38477852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chitosan coated pH/redox-responsive hyaluronic acid micelles for enhanced tumor targeted co-delivery of doxorubicin and siPD-L1.
    Song P; Lu Z; Jiang T; Han W; Chen X; Zhao X
    Int J Biol Macromol; 2022 Dec; 222(Pt A):1078-1091. PubMed ID: 36183754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of LAG-3/FGL1 pathway on immune evasive contexture and clinical outcomes in advanced urothelial carcinoma.
    Yoshida T; Nakamoto T; Atsumi N; Ohe C; Sano T; Yasukochi Y; Tsuta K; Kinoshita H
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39043605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway.
    Li X; Wang S; Mu W; Barry J; Han A; Carpenter RL; Jiang BH; Peiper SC; Mahoney MG; Aplin AE; Ren H; He J
    J Exp Clin Cancer Res; 2022 Jan; 41(1):41. PubMed ID: 35086548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma.
    Lin M; He J; Zhang X; Sun X; Dong W; Zhang R; Xu Y; Lv L
    J Clin Invest; 2023 May; 133(9):. PubMed ID: 37115693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FGL1 in plasma extracellular vesicles is correlated with clinical stage of lung adenocarcinoma and anti-PD-L1 response.
    Zhang Y; Zhang K; Wen H; Ge D; Gu J; Zhang C
    Clin Exp Immunol; 2024 Mar; 216(1):68-79. PubMed ID: 38146642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene augmented nuclear-targeting sonodynamic therapy via Nrf2 pathway-based redox balance adjustment boosts peptide-based anti-PD-L1 therapy on colorectal cancer.
    Wan G; Chen X; Wang H; Hou S; Wang Q; Cheng Y; Chen Q; Lv Y; Chen H; Zhang Q
    J Nanobiotechnology; 2021 Oct; 19(1):347. PubMed ID: 34715867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth.
    Kwak G; Kim D; Nam GH; Wang SY; Kim IS; Kim SH; Kwon IC; Yeo Y
    ACS Nano; 2017 Oct; 11(10):10135-10146. PubMed ID: 28985469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-delivery of PD-L1- and EGFR-targeting siRNAs by synthetic PEG
    Man RCH; Qiu Y; Leung SWS; Fruhwirth GO; Lam JKW
    Eur J Pharm Biopharm; 2024 Feb; 195():114177. PubMed ID: 38185193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IR792-MCN@ZIF-8-PD-L1 siRNA drug delivery system enhances photothermal immunotherapy for triple-negative breast cancer under near-infrared laser irradiation.
    Wang Y; Wang H; Song Y; Lv M; Mao Y; Song H; Wang Y; Nie G; Liu X; Cui J; Zou X
    J Nanobiotechnology; 2022 Mar; 20(1):96. PubMed ID: 35236356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Manipulating immune system using nanoparticles for an effective cancer treatment: Combination of targeted therapy and checkpoint blockage miRNA.
    Nguyen HT; Phung CD; Tran TH; Pham TT; Pham LM; Nguyen TT; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
    J Control Release; 2021 Jan; 329():524-537. PubMed ID: 32971203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer.
    Zhu W; Bai Y; Zhang N; Yan J; Chen J; He Z; Sun Q; Pu Y; He B; Ye X
    J Mater Chem B; 2021 May; 9(20):4201-4210. PubMed ID: 33997867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engineered EGCG-Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy.
    Wu P; Zhang H; Yin Y; Sun M; Mao S; Chen H; Deng Y; Chen S; Li S; Sun B
    Adv Sci (Weinh); 2022 May; 9(15):e2105894. PubMed ID: 35486032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles.
    Lai X; Yao F; An Y; Li X; Yang XD
    Molecules; 2023 Mar; 28(6):. PubMed ID: 36985529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.